FOR IMMEDIATE RELEASE ON Oct. 5th , 2026

FLAMMA ACQUIRES API MANUFACTURING SITE IN ITALY FROM LUNDBECK

Acquisition will Establish Four cGMP Manufacturing Facilities in Italy and Strengthens Flamma's Position in the Global Small Molecule CDMO Marketplace

Bergamo, Italy, October 5, 2026 – Flamma, a global Contract Development and Manufacturing Organization (CDMO) focused on small molecule APIs, peptides and advanced intermediates, today announced that it has entered into an agreement to acquire Lundbeck Pharmaceuticals Italy SpA ("LuPI") from H. Lundbeck A/S ("Lundbeck"). The transaction is subject to customary closing conditions and is expected to close on January 1, 2027.

The acquisition marks another important step in Flamma's strategic expansion and reinforces the company's commitment to investing in high-quality pharmaceutical manufacturing infrastructure. Upon completion of the transaction, Flamma will operate four cGMP API manufacturing sites within close proximity to one another in Northern Italy, along with its manufacturing operations in China and in the United States.

The Padova facility contributes up to 220 m³ of manufacturing capacity, increasing Flamma's total capacity to approximately 1,100 m³ in Italy. The site also adds a state-of-the-art API manufacturing workshop, recently approved by AIFA ,together with advanced technological capabilities including hydrogenation, micronization, high-pressure chemistry, hazardous chemistry, and high-containment manufacturing with a longstanding reputation for quality, operational excellence, and the successful development and manufacture of complex APIs.

By combining expanded manufacturing capacity with deep technical expertise, regulatory excellence and a highly experienced workforce, the acquisition further enhances Flamma's ability to support pharmaceutical innovators from early-stage development through commercial supply. It also advances Flamma's long-term strategy of building a differentiated global CDMO platform focused on complex small molecule APIs, as well as high-value amino acids and peptides, combining scientific expertise, manufacturing excellence, and supply chain reliability to serve pharmaceutical innovators worldwide.

Lazard is acting as exclusive financial advisor and NCTM Advant as legal advisor to Flamma in connection with the transaction. Canaccord Genuity is acting as exclusive financial advisor and Baker McKenzie as legal advisor to Lundbeck.

Gian Paolo Negrisoli, Chairman of the Board of Directors and CEO of Flamma, said:

"The acquisition of the Padova site represents a strategic investment in Flamma's growth and in the future of our customers. Beyond the expansion of our manufacturing footprint, we are adding significant scientific, technical and operational capabilities that will strengthen our ability to deliver innovative solutions across the entire pharmaceutical development lifecycle of small molecules and peptides."

Tine Bryan Stensbøl, interim Head of Product Development & Supply, Lundbeck, said:

"We are very pleased to have found a strong fit with Flamma Group as the new owner of LuPI. Our facility in Padova has a long and proud track record as part of the Lundbeck family, however, Lundbeck's future need for small molecule manufacturing can expectedly be covered by our facility in Lumsås, Denmark. Consequently, we firmly believe that the decision to divest is the right move for both LuPI and for Lundbeck."

About Flamma:

Founded in 1950, Flamma is a global, fully integrated CDMO specializing in small molecule development and manufacturing. With facilities in Italy, China, and the USA, more than 1,100 employees, and 20% dedicated to R&D, we deliver **Chemistry with a Human Touch** that combines scientific precision, strategic thinking, and a deeply collaborative approach. For additional information, we encourage you to visit www.flammagroup.com

About LuPI:

Lundbeck Pharmaceuticals Italy SpA is a high-quality chemical pharmaceutical facility located in Padova, Italy. The site is authorized for active pharmaceutical ingredients (API) manufacturing for human and veterinarian products. It has 140 employees and offers multi-purpose production across several manufacturing facilities with advanced automation and control systems. The company is supported by a state-of-the-art R&D center and robust environmental, health, and safety (EHS) infrastructure, underscoring its commitment to innovation, sustainability, and operational excellence."

About H. Lundbeck A/S:

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.